Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparation ManufacturingUnited States
Last verified 4 days agomatinasbiopharma.com
Matinas BioPharma Holdings, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 2013, the company has made significant strides in developing innovative lipid-based drug delivery systems, particularly for the treatment of infectious diseases and other serious health conditions.
Matinas BioPharma is renowned for its unique core product, the MAT9001, which leverages its proprietary lipid nanocrystal technology to enhance the bioavailability of therapeutic agents. This innovative approach positions the company at the forefront of the pharmaceutical sector, addressing critical needs in drug delivery.
With a commitment to advancing healthcare solutions, Matinas BioPharma has achieved notable milestones, including strategic partnerships and successful clinical trials, solidifying its market position as a leader in pharmaceutical innovation.
23
DitchCarbon score
-19 vs industry average
Matinas BioPharma Holdings, Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Matinas BioPharma Holdings, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Very Low
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
0.243
02025
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 1
•••kg CO₂e
Scope 2
•••kg CO₂e
Scope 3
•••kg CO₂e
Total reported
•••kg CO₂e
Scope 3 accounts for ••• of total emissions.
Matinas BioPharma Holdings, Inc.'s reported carbon emissions
Matinas BioPharma Holdings, Inc., a US-based Pharmaceutical Preparation Manufacturing company, reported its 2022 carbon emissions with Scope 1 emissions of 404,000 kg CO2e and Scope 2 emissions of 282,600 kg CO2e. For 2021, the company disclosed Scope 1 emissions of 533,000,000 kg CO2e; Scope 2 and Scope 3 data were not provided for that year. Matinas BioPharma has not publicly committed to specific carbon reduction targets, nor has it adopted Science Based Targets (SBTi).
Assessing Matinas BioPharma Holdings, Inc. as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Matinas BioPharma Holdings, Inc. and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Matinas BioPharma Holdings, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Matinas BioPharma Holdings, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
See details
Not active
Carbon Disclosure Project
See details
Not active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
See details
Not active
RE 100
See details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsCompanyCountryIndustryLast updatedScoreDetails
Matinas BioPharma Holdings, Inc.4 days ago
23
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more